학술논문
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Document Type
Article
Author
Javle, Milind; Roychowdhury, Sameek; Kelley, Robin Kate; Sadeghi, Saeed; Macarulla, Teresa; Weiss, Karl Heinz; Waldschmidt, Dirk-Thomas; Goyal, Lipika; Borbath, Ivan; El-Khoueiry, Anthony; Borad, Mitesh J; Yong, Wei Peng; Philip, Philip A; Bitzer, Michael; Tanasanvimon, Surbpong; Li, Ai; Pande, Amit; Soifer, Harris S; Shepherd, Stacie Peacock; Moran, Susan; Zhu, Andrew X; Bekaii-Saab, Tanios S; Abou-Alfa, Ghassan K
Source
The Lancet Gastroenterology & Hepatology; October 2021, Vol. 6 Issue: 10 p803-815, 13p
Subject
Language
ISSN
24681253
Abstract
Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2fusions or rearrangements occur in 10–16% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2alterations, and previous gemcitabine-based treatment.